Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-IFN for clinical cure in inactive HBsAg carriers
ChiCTR2100049302Phase 4Not yet recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegylated interferon alpha in hepatitis B (HBV) (2 arms), sponsored by Beijing YouAn Hospital. Primary endpoint: Clearance of hepatitis B virus surface antigen at 96 weeks. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
pegylated interferon alpha
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR2100049302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049302.